Artiva Biotherapeutics, Inc.(ARTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARTV Artiva Biotherapeutics, Inc.

Trading 11-04 12:57:12 EST

11.04

+0.32

+2.99%

High11.14	Low10.50	Vol13.53K
Open10.77	D1 Closing10.72	Amplitude5.92%
Mkt Cap268.13M	Tradable Cap44.41M	Total Shares24.29M
T/O147.63K	T/O Rate0.34%	Tradable Shares4.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":11.04,"timestamp":1730742974099,"preClose":10.72,"halted":0,"volume":13532,"delay":0,"floatShares":4022264,"shares":24287144,"eps":-40.188656,"marketStatus":"Trading","change":0.32,"latestTime":"11-04 12:57:12 EST","open":10.77,"high":11.135,"low":10.5,"amount":147633.700508,"amplitude":0.059235,"askPrice":11.1,"askSize":200,"bidPrice":10.88,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-40.188656,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1730754000000},"marketStatusCode":2,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":10.72,"postHourTrading":{"tag":"盘后","latestPrice":10.72,"preClose":10.72,"latestTime":"16:02 EDT","volume":670,"amount":7182.4,"timestamp":1730491332484},"volumeRatio":0.527396},"requestUrl":"/m/hq/s/ARTV","defaultTab":"news","newsList":[{"id":"2477394643","title":"BRIEF-Artiva Biotherapeutics Appoints Alison Moore To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2477394643","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477394643?lang=en_us&edition=fundamental","pubTime":"2024-10-23 05:50","pubTimestamp":1729633835,"startTime":"0","endTime":"0","summary":"Oct 22 (Reuters) - Artiva Biotherapeutics   :   * ARTIVA BIOTHERAPEUTICS APPOINTS ALISON MOORE, PH.D., TO ITS BOARD OF DIRECTORSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","BK4139","ARTV","BK4505"],"gpt_icon":0},{"id":"2477360977","title":"Artiva Biotherapeutics Appoints Alison Moore, Ph.d., to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2477360977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477360977?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA6LNW4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139","BK4121","ALLO","BK4505","CDXS"],"gpt_icon":0},{"id":"2477360441","title":"Press Release: Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2477360441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477360441?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 22, 2024  -- Artiva Biotherapeutics, Inc. , a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer  of Codexis Inc. , a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics , a pioneering clinical-stage company advancing CAR T-cell therapies.Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva's lead program, AlloNK , is an allogeneic, off-the-shelf, non-genetica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4139","BK4232","BK4022","ARTV","R","CTO","BK4160"],"gpt_icon":0},{"id":"2466036495","title":"Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2466036495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466036495?lang=en_us&edition=fundamental","pubTime":"2024-09-11 04:05","pubTimestamp":1725998700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  10, 2024  (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/10/2944113/0/en/Artiva-Biotherapeutics-to-Participate-in-the-2024-Cantor-Fitzgerald-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK4137","BK4139","ARTV"],"gpt_icon":0},{"id":"2465853184","title":"Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2465853184","media":"seekingalpha","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465853184?lang=en_us&edition=fundamental","pubTime":"2024-09-05 04:40","pubTimestamp":1725482411,"startTime":"0","endTime":"0","summary":"On 06/11/24, I published an article on Affimed focused on my belief the company’s upcoming acimtamig update would be positive. It was, and Affimed’s stock popped the next day.The stock has since dropped to below $4/s based, in my opinion, on investor's perceptions that a dilutive capital raise is coming soon.AFMD’s 2Q ’24 Earnings Call is scheduled for tomorrow, 09/05/24. And we are due for an acimtamig and AFM24 3Q ’24 update before the end of the month.Abstracts for ESMO’24 are posted on 09/06/24 and the WCLC starts 09/07/24…will we get the AFM24 update before acimtamig's?It is due, in my opinion, to the company's cash level  and its potential need to raise capital within the next 6-12 months. I'll discuss why I am less concerned with the fact the company needs to raise ca","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339282297/image_1339282297.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339282297/image_1339282297.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4719046-affimed-acimtamig-and-afm24-updates-positive-catalysts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00B19Z3581.USD","LU0170899867.USD","IE0002270589.USD","LU0289739699.SGD","LU0868494617.USD","LU0456855351.SGD","IE00BLSP4452.SGD","LU0225771236.USD","AFMD","BK4568","RHHBY","LU0225284248.USD","IE00B19Z3B42.SGD","ROIV","ARTV","SG9999003800.SGD","LU0122379950.USD","BK4588","LU0234572021.USD","LU1883839398.USD","BK4585","LU1894683348.USD","LU0985481810.HKD","LU0306807586.USD","SG9999001176.USD","BK4581","IE00BLSP4239.USD","LU1057294990.SGD","BK4139","SG9999013999.USD","LU0306806265.USD","LU1066051498.USD","LU0321505439.SGD","LU0058720904.USD","IE000M9KFDE8.USD","03165","LU1066053197.SGD","BK4533","LU0321505868.SGD","BK4007","BK4534","IE00BBT3K403.USD","SG9999002232.USD","SG9999011175.SGD","LU1894683264.USD","SG9999001176.SGD","BK4550","LU1023059063.AUD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2464876761","title":"Buy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2464876761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464876761?lang=en_us&edition=fundamental","pubTime":"2024-09-03 18:28","pubTimestamp":1725359287,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating on August 30. Tyler Van Buren has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-artiva-biotherapeutics-on-promising-allonk-developments-and-trial-optimism?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-artiva-biotherapeutics-on-promising-allonk-developments-and-trial-optimism?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"gpt_icon":0},{"id":"2463776514","title":"Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2463776514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463776514?lang=en_us&edition=fundamental","pubTime":"2024-08-31 00:08","pubTimestamp":1725034080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 30, 2024 12:08 ET (16:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2463758740","title":"Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2463758740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463758740?lang=en_us&edition=fundamental","pubTime":"2024-08-30 21:25","pubTimestamp":1725024329,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) and keeping the price target at $23....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-artiva-biotherapeutics-amidst-clinical-advancements-and-strong-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-artiva-biotherapeutics-amidst-clinical-advancements-and-strong-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"gpt_icon":0},{"id":"2463216901","title":"Artiva Biotherapeutics Reports Wider Q2 Loss, No Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2463216901","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463216901?lang=en_us&edition=fundamental","pubTime":"2024-08-30 05:31","pubTimestamp":1724967096,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics  reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier.Four analysts surveyed by Capital IQ expected a loss of $4.40.No revenue for the quarter ended June 30 was reported. Revenue a year earlier was $3.5 million.Four analysts polled by Capital IQ estimated $80,000.As of June 30, the company said it had $46.6 million in cash, cash equivalents, and short-term investments. It said the $179 million in gross proceeds from its initial public offering in July extends cash runway at least through the end of 2026 and through key clinical data milestones.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARTV"],"gpt_icon":0},{"id":"2463900212","title":"Artiva Biotherapeutics GAAP EPS of -$22.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2463900212","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463900212?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:25","pubTimestamp":1724963153,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics press release  : Q2  GAAP EPS of -$22.00.As of June 30, 2024, Artiva had cash, cash equivalents, and short-term investments of $46.6 million. In addition, Artiva completed its IPO in July 2024 in which it sold 14,920,000 shares of its common stock, including partial exercise of the overallotment option, for gross proceeds of $179.0 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4145302-artiva-biotherapeutics-gaap-eps-of-22_00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ARTV"],"gpt_icon":0},{"id":"2463290874","title":"Artiva Biotherapeutics Q2 EPS $(22.00) Down From $(14.09) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2463290874","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463290874?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:14","pubTimestamp":1724962457,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(22.00) per share. This is a 56.14 percent decrease over losses of $(14.09) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40638095/artiva-biotherapeutics-q2-eps-22-00-down-from-14-09-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Artiva Biotherapeutics Q2 EPS $(22.00) Down From $(14.09) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2463829751","title":"Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2463829751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463829751?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:05","pubTimestamp":1724961901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240829:nTUA9HYTJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2463529792","title":"Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2463529792","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463529792?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:05","pubTimestamp":1724961900,"startTime":"0","endTime":"0","summary":"Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK exploring","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/29/2938098/0/en/Artiva-Biotherapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139","IPO","BK4077","SLE"],"gpt_icon":0},{"id":"2459897713","title":"Wedbush Initiates Artiva Biotherapeutics at Outperform With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2459897713","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459897713?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:14","pubTimestamp":1723551243,"startTime":"0","endTime":"0","summary":"Price: 11.30, Change: +0.08, Percent Change: +0.71","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARTV"],"gpt_icon":0},{"id":"2459703349","title":"Wedbush Initiates Artiva Biotherapeutics at Outperform With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2459703349","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459703349?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:14","pubTimestamp":1723551243,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2459974688","title":"Artiva Biotherapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2459974688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459974688?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:36","pubTimestamp":1723548960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 13, 2024 07:36 ET (11:36 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2459597691","title":"Buy Rating Affirmed for Artiva Biotherapeutics Amid Promising NK Cell Therapy Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2459597691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459597691?lang=en_us&edition=fundamental","pubTime":"2024-08-13 18:58","pubTimestamp":1723546700,"startTime":"0","endTime":"0","summary":"Gil Blum, an analyst from Needham, has initiated a new Buy rating on Artiva Biotherapeutics, Inc. (ARTV). Gil Blum has given his Buy rating due to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-artiva-biotherapeutics-amid-promising-nk-cell-therapy-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-artiva-biotherapeutics-amid-promising-nk-cell-therapy-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"gpt_icon":0},{"id":"2459040973","title":"Artiva Biotherapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2459040973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459040973?lang=en_us&edition=fundamental","pubTime":"2024-08-13 18:44","pubTimestamp":1723545891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nFWN3K00Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4207","ARTV","BK4566","BK4127","COWN","TD"],"gpt_icon":0},{"id":"2459732529","title":"Cantor Fitzgerald Initiates Artiva Biotherapeutics at Overweight With $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2459732529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459732529?lang=en_us&edition=fundamental","pubTime":"2024-08-13 18:40","pubTimestamp":1723545630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2459997325","title":"Jefferies Initiates Artiva Biotherapeutics at Buy With $21 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2459997325","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459997325?lang=en_us&edition=fundamental","pubTime":"2024-08-13 18:40","pubTimestamp":1723545621,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["ARTV","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.artivabio.com","stockEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":-0.3181},{"period":"3month","weight":-0.083},{"period":"6month","weight":-0.1067},{"period":"ytd","weight":-0.1067}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Artiva Biotherapeutics, Inc.","nameEN":"Artiva Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Artiva Biotherapeutics, Inc.(ARTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Artiva Biotherapeutics, Inc.(ARTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Artiva Biotherapeutics, Inc.,ARTV,Artiva Biotherapeutics, Inc.股票,Artiva Biotherapeutics, Inc.股票老虎,Artiva Biotherapeutics, Inc.股票老虎国际,Artiva Biotherapeutics, Inc.行情,Artiva Biotherapeutics, Inc.股票行情,Artiva Biotherapeutics, Inc.股价,Artiva Biotherapeutics, Inc.股市,Artiva Biotherapeutics, Inc.股票价格,Artiva Biotherapeutics, Inc.股票交易,Artiva Biotherapeutics, Inc.股票购买,Artiva Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Artiva Biotherapeutics, Inc.(ARTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Artiva Biotherapeutics, Inc.(ARTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}